NASDAQ:ALBT Avalon GloboCare (ALBT) Stock Price, News & Analysis $0.41 -0.01 (-1.43%) Closing price 04:00 PM EasternExtended Trading$0.40 -0.01 (-3.14%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Avalon GloboCare Stock (NASDAQ:ALBT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Avalon GloboCare alerts:Sign Up Key Stats Today's Range$0.40▼$0.4350-Day Range$0.40▼$1.4952-Week Range$0.34▼$4.74Volume138,948 shsAverage Volume2.42 million shsMarket Capitalization$3.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection. Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies. Its technology platforms include exoSTAMP, designed for highly sensitive isolation and analysis of circulating exosomes, and exoSC, aimed at scalable manufacturing of exosome-based products. The company maintains strategic collaborations with academic and clinical partners to accelerate development timelines and broaden the potential application of its technologies. These partnerships support Avalon’s efforts to optimize manufacturing processes, refine product specifications and initiate clinical trials in oncology and, potentially, viral diseases where cell therapy approaches can address unmet medical needs. Founded in 2016 and publicly listed on NASDAQ under the ticker ALBT, Avalon GloboCare is led by Dr. Leem Chao, its Chairman and Chief Executive Officer. Under his leadership, the company has expanded its footprint across key biopharma hubs and continues to advance a diversified portfolio of innovative therapies and diagnostics designed to improve patient outcomes worldwide.AI Generated. May Contain Errors. Read More Avalon GloboCare Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreALBT MarketRank™: Avalon GloboCare scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingAvalon GloboCare has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAvalon GloboCare has only been the subject of 1 research reports in the past 90 days.Read more about Avalon GloboCare's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Avalon GloboCare is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avalon GloboCare is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Avalon GloboCare's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.70% of the float of Avalon GloboCare has been sold short.Short Interest Ratio / Days to CoverAvalon GloboCare has a short interest ratio ("days to cover") of 0.32, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalon GloboCare has recently increased by 31.09%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvalon GloboCare does not currently pay a dividend.Dividend GrowthAvalon GloboCare does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest4 people have searched for ALBT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added Avalon GloboCare to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avalon GloboCare insiders have not sold or bought any company stock.Percentage Held by Insiders24.19% of the stock of Avalon GloboCare is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.42% of the stock of Avalon GloboCare is held by institutions.Read more about Avalon GloboCare's insider trading history. Receive ALBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalon GloboCare and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALBT Stock News HeadlinesExclusive: Avalon GloboCare gets $125K conditional grant for teaming with AWS for 'agentic' AI video platformApril 21, 2026 | msn.comAvalon Quantum AI teams up with Caylent and Amazon Web Services on Agentic AI Platform DevelopmentApril 21, 2026 | globenewswire.comOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.May 6 at 1:00 AM | Reagan Gold Group (Ad)Avalon GloboCare (ALBT) surges over 36% after hours: Here's what is happeningApril 9, 2026 | msn.comAvalon GloboCare (ALBT) Surges Over 36% After Hours: Here's What Is HappeningApril 9, 2026 | benzinga.comAvalon GloboCare Corp.April 1, 2026 | edition.cnn.comAvalon Quantum AI Announces Strategic Collaboration with Caylent, an Amazon Web Services Premier Tier Partner, to Advance its Catch-Up Product into a Fully Autonomous Agentic ...April 1, 2026 | markets.businessinsider.comAvalon GloboCare Completes Private Placement to Raise CapitalMarch 21, 2026 | theglobeandmail.comSee More Headlines ALBT Stock Analysis - Frequently Asked Questions How have ALBT shares performed this year? Avalon GloboCare's stock was trading at $1.20 at the beginning of 2026. Since then, ALBT stock has decreased by 65.5% and is now trading at $0.4140. How were Avalon GloboCare's earnings last quarter? Avalon GloboCare Corp. (NASDAQ:ALBT) released its earnings results on Monday, March, 30th. The company reported $0.46 EPS for the quarter. When did Avalon GloboCare's stock split? Avalon GloboCare's stock reverse split before market open on Monday, October 28th 2024.The 1-15 reverse split was announced on Thursday, October 24th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Avalon GloboCare? Shares of ALBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avalon GloboCare own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avalon GloboCare investors own include Sangamo Therapeutics (SGMO), Ford Motor (F), Pfizer (PFE), Plug Power (PLUG), NVIDIA (NVDA), Intel (INTC). Company Calendar Last Earnings3/30/2026Today5/06/2026Next Earnings (Estimated)5/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ALBT's financial health is in the Yellow zone, according to TradeSmith. ALBT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALBT Previous SymbolNASDAQ:AVCO CIK1630212 Webwww.avalon-globocare.com Phone(732) 780-4400Fax732-780-5600Employees5Year Founded2014Profitability EPS (Trailing Twelve Months)($3.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.26 million Net MarginsN/A Pretax Margin-29,122.62% Return on EquityN/A Return on Assets-64.78% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.11 Sales & Book Value Annual Sales$1.26 million Price / Sales2.73 Cash FlowN/A Price / Cash FlowN/A Book Value($3.77) per share Price / Book-0.11Miscellaneous Outstanding Shares8,320,000Free Float6,310,000Market Cap$3.44 million OptionableNot Optionable Beta-0.04 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ALBT) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely, LLC | SponsoredGold surged 600 dollars last time this indicator peakedThe Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...Porter & Company | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredMilitary ‘Dark Energy’ to Power AIWhen it was put inside U.S. tanks, they moved almost silently and produced no smoke. Now, Elon Musk is using t...Altimetry | SponsoredRevealed: The World’s First Trillion-Dollar RobotJensen Huang stood in Las Vegas and laid out Nvidia's vision for building the world's first trillion-dollar ro...Weiss Ratings | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
